IP Library › Granted Patent US 12,228,571
Granted Patent B2
US 12,228,571 · App. 16/972,956 · Granted Feb 18, 2025

Cell-based assay for measuring drug product potency

Inventors: Brian Kaspar (New Albany, OH); Allan Kaspar (Carlsbad, CA); Kevin Foust (Poway, CA); Martin Fugere (San Diego, CA); Eunhye Park (San Diego, CA); Gretchen Thomsen (San Diego, CA); Fengrong Zuo (San Diego, CA)
Assignee: Novartis AG
G01N33/56966A61K48/005C12N5/0619C12N15/52C12N15/63C12N15/86C12N15/87G01N1/30A61K48/00C12N2501/11C12N2501/115C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,228,571
App. No.
16/972,956
Granted
Feb 18, 2025
Kind
B2
Abstract

The invention relates to an in vitro quantative cell-based assay that uses a primary mouse cell model system permissive to viral vector infection and a quantitative high content image-based system for determining potency of a transgene-expressing viral vector drug product for lot disposition.

Claims (43)

1. An in vitro method for measuring transgene expression, comprising:

a) providing a first plurality of terminally differentiated neural progenitor cells (NPCs) comprising a homozygous Survival Motor Neuron (SMN1)−/− mutation;

b) transducing the first plurality of terminally differentiated NPCs with a test sample comprising an AAV9 viral vector comprising a sequence encoding a Survival Motor Neuron (SMN1) protein;

c) incubating the transduced first plurality of terminally differentiated NPCs under conditions sufficient to express the SMN1 protein;

d) contacting the first plurality of terminally differentiated NPCs from (c) with a molecule specific for the SMN1 protein;

e) imaging the first plurality of terminally differentiated NPCs to obtain an integrated fluorescent intensity per cell (IFI-C) assay readout; and

f) determining the expression of the SMN1 protein based on the IFI-C readout,

wherein said first plurality of terminally differentiated NPCs is produced by terminally differentiating neural progenitor cells isolated from the cortex of an SMN1−/− mouse embryo, and wherein the SMN1−/− mutation comprises a deletion of SMN1 exon 7 (Δ7).

2. The method of claim 1 , wherein the incubating step c) is followed by fixing and permeabilizing the first plurality of terminally differentiated NPCs.

3. The method of claim 1 , further comprising:

g) providing a second plurality of terminally differentiated NPCs comprising a homozygous Survival Motor Neuron (SMN1)−/− mutation;

h) transducing the second plurality of terminally differentiated NPCs with a reference standard comprising the AAV9 viral vector;

i) incubating the transduced second plurality of terminally differentiated NPCs under conditions sufficient to express the SMN1 protein;

j) contacting the second plurality of terminally differentiated NPCs from (i) with a molecule specific for the SMN1 protein;

k) imaging the second plurality of terminally differentiated NPCs to obtain an integrated fluorescent intensity per cell (IFI-C) assay readout; and

l) comparing the IFI-C of the first plurality of terminally differentiated NPCs with the IFI-C of the second plurality of terminally differentiated NPCs,

thereby determining the relative potency of the AAV9 viral vector of the test sample relative to the reference standard,

wherein said second plurality of terminally differentiated NPCs is produced by terminally differentiating neural progenitor cells isolated from the cortex of an SMN1−/− mouse embryo, and wherein the SMN1−/− mutation comprises a deletion of SMN1 exon 7 (Δ7).

4. The method of claim 3 , wherein the incubating step (i) is followed by fixing and permeabilizing the second plurality of terminally differentiated NPCs.

5. The method of claim 3 , wherein the first and second pluralities of terminally differentiated neural progenitor cells (NPCs) are terminally differentiated by:

a. culturing the NPCs in serum free culture media containing Epidermal Growth Factor (EGF) and Fibroblast Growth Factor-basic (bFGF) to form neurospheres;

b. dissociating said neurospheres to produce dissociated NPCs; and

C. culturing the dissociated NPCs in serum-enriched media without growth factors,

thereby producing terminally differentiated NPCs.

6. The method of claim 3 , wherein said first and second pluralities of NPCs are transduced by the test sample and the reference standard at at least two different multiplicities of infection (MOI) of the AAV9 viral vector.

7. The method of claim 5 , wherein the first and second pluralities of NPCs are transduced by the test sample and the reference sample at 5 MOIs comprising 300,000, 150,000, 75,000, 37,500, and 18,750 viral particles per cell.

8. The method of claim 3 , wherein the comparing step (l) comprises plotting a standard curve of MOI versus IFI-C for each of the test sample and the reference standard.

9. The method of claim 3 , wherein the comparing step (l) comprises calculating a linear regression of log MOI versus IFI-C for each of the test sample and the reference standard, thereby deriving a test sample slope and a reference standard slope.

10. The method of claim 5 , wherein determining the relative potency of the viral vector is performed by parallel line analysis (PLA), and wherein the PLA comprises measuring a slope ratio of the test sample slope against the reference standard slope.

11. The method of claim 10 , wherein the reference standard slope is greater than or equal to 1.02E+05, and wherein the slope ratio is between 0.69-1.45.

12. The method of claim 10 , further comprising calculating an assay dynamic window of the reference standard, wherein the assay dynamic window is greater than or equal to 2.69.

13. The method of claim 1 , wherein the AAV9 viral vector comprises AAV serotype 2 inverted terminal repeats (ITRs).

14. The method of claim 1 , wherein the AAV9 viral vector comprises a sequence encoding cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB) operably linked to the sequence encoding the SMN1 protein.

15. The method of claim 1 , wherein the viral vector comprises a sequence of SEQ ID NO: 1.

16. The method of claim 1 , wherein the IFI-C readout reflects a measurement of protein expression.

17. The method of claim 1 , wherein the molecule that is specific for the SMN1 protein comprises an antibody, an antibody fragment, or an aptamer.

18. The method of claim 17 , wherein the antibody is provided at a concentration of about 4 μg/mL.

19. The method of claim 1 , wherein the molecule comprises a detectable label.

20. The method of claim 1 , further comprising contacting the terminally differentiated NPCs with a second molecule that specifically recognizes the molecule specific for the SMN1 protein.

21. The method of claim 20 , wherein the second molecule comprises a detectable label.

22. The method of claim 20 , wherein the second molecule comprises an antibody, an antibody fragment or an aptamer.

23. The method of claim 2 , wherein the first plurality of terminally differentiated NPCs are contacted with an anti-nuclear detectable label following the fixing and permeabilizing step.

24. The method of claim 1 , wherein the terminally differentiated NPCs are on a solid surface.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2021
From: NOVARTIS GENE THERAPIES, INC.
To: NOVARTIS AG
Reel/Frame 056017/0649 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2021
From: KASPAR, BRIAN; KASPAR, ALLAN; FOUST, KEVIN; FUGERE, MARTIN; PARK, EUNHYE; THOMSEN, GRETCHEN; ZUO, FENGRONG
To: AVEXIS INC.
Reel/Frame 056017/0684 →
CHANGE OF NAME Recorded Apr 23, 2021
From: AVEXIS, INC.
To: NOVARTIS GENE THERAPIES, INC.
Reel/Frame 056035/0530 →
Continuity (2)
Provisional Application 62682263 · Jun 8, 2018
Related Publication 20210255185A1 · Aug 19, 2021
References Cited (180)
US 5139941A · Muzyczka et al. · 1992 [cited by applicant]
US 5173414A · Lebkowski et al. · 1992 [cited by applicant]
US 5173418A · Molin et al. · 1992 [cited by applicant]
US 5786211A · Johnson · 1998 [cited by applicant]
US 5871982A · Wilson et al. · 1999 [cited by applicant]
US 6258595B1 · Gao et al. · 2001 [cited by applicant]
US 6376237B1 · Colosi · 2002 [cited by applicant]
US 6756207B1 · Giuliano et al. · 2004 [cited by applicant]
US 7198951B2 · Gao et al. · 2007 [cited by applicant]
US 7704721B2 · Wright et al. · 2010 [cited by applicant]
US 8361977B2 · Baker et al. · 2013 [cited by applicant]
US 8980853B2 · Bennett et al. · 2015 [cited by applicant]
US 9415121B2 · Kaspar et al. · 2016 [cited by applicant]
US 10793861B2 · Kaspar et al. · 2020 [cited by applicant]
US 20020045591A1 · Geiger · 2002 [cited by examiner]
US 20050053922A1 · Schaffer et al. · 2005 [cited by applicant]
US 20050153446A1 · Steindler · 2005 [cited by examiner]
US 20090202490A1 · Schaffer et al. · 2009 [cited by applicant]
US 20120177605A1 · Kaspar et al. · 2012 [cited by applicant]
US 20130072548A1 · Wright et al. · 2013 [cited by applicant]
US 20150252384A1 · Kaspar et al. · 2015 [cited by applicant]
US 20160038613A1 · Kaspar et al. · 2016 [cited by applicant]
US 20160152955A1 · Sakamoto et al. · 2016 [cited by applicant]
US 20160272976A1 · Kaspar et al. · 2016 [cited by applicant]
US 20170216458A1 · Kaspar et al. · 2017 [cited by applicant]
US 20180036431A1 · Kaspar et al. · 2018 [cited by applicant]
US 20190336618A1 · Kaspar · 2019 [cited by applicant]
US 20200179467A1 · Kaspar et al. · 2020 [cited by applicant]
US 20210317474A1 · Kaspar et al. · 2021 [cited by applicant]
CN 105087650A · 2015 [cited by applicant]
EP 2933335A1 · 2015 [cited by applicant]
EP 3054006A1 · 2016 [cited by applicant]
WO WO9513365A1 · 1995 [cited by applicant]
WO WO9513392A1 · 1995 [cited by applicant]
WO WO9617947A1 · 1996 [cited by applicant]
WO WO9706243A1 · 1997 [cited by applicant]
WO WO9708298A1 · 1997 [cited by applicant]
WO WO9709441A2 · 1997 [cited by applicant]
WO WO9721825A1 · 1997 [cited by applicant]
WO WO9809657A2 · 1998 [cited by applicant]
WO WO9911764A2 · 1999 [cited by applicant]
WO WO0183692A2 · 2001 [cited by applicant]
WO WO2004113494A2 · 2004 [cited by applicant]
WO WO2005046598A2 · 2005 [cited by applicant]
WO WO2010002846A1 · 2010 [cited by applicant]
WO WO2010129021A1 · 2010 [cited by applicant]
WO WO2011079018A2 · 2011 [cited by applicant]
WO WO2011094198A1 · 2011 [cited by applicant]
WO WO2013190059A1 · 2013 [cited by applicant]
WO WO2013192005A2 · 2013 [cited by applicant]
WO WO2014022582A1 · 2014 [cited by examiner]
WO WO2014178863A1 · 2014 [cited by applicant]
WO WO2015013148A2 · 2015 [cited by applicant]
WO WO2015031392A9 · 2015 [cited by applicant]
WO WO2016004319A1 · 2016 [cited by applicant]
WO WO2016100575A1 · 2016 [cited by applicant]
WO WO2016128407A1 · 2016 [cited by applicant]
WO WO2016128408A1 · 2016 [cited by applicant]
WO WO2017160360A2 · 2017 [cited by applicant]
WO WO2017173283A1 · 2017 [cited by applicant]
WO WO2017181113A1 · 2017 [cited by applicant]
WO WO2018055206A1 · 2018 [cited by applicant]
WO WO2019011817A1 · 2019 [cited by applicant]
WO WO2019094253A1 · 2019 [cited by applicant]
WO WO2019236949A1 · 2019 [cited by applicant]
Fawaz et al., “A potency assay for a replication incompetent adenovirus type 5 carrying a human fgf-4 gene,” Anal. Biochem., 2005, vol. 342, No. 1, pp. 34-44. [cited by examiner]
Klement et al., “Ataxin-1 Nuclear Localization and Aggregation: Role in Polyglutamine-Induced Disease in SCA1 Transgenic Mice,” Cell, 1998, vol. 95, issue 1, pp. 41-53. [cited by examiner]
Miller et al., “460. A quantitative method for determining adenovirus gene transfer efficiency with established and primary human tumor cell cultures,” Mol. Therapy, 2001, vol. 3, No. 5, p. S165. [cited by examiner]
Qu, W. et al., “Calcium-ion-modulated ceramic hydroxyapatite resin for the scalable purification of recombinant Adeno-Associated Virus serotype 9,” Journal of Chromatography B, 2015, vol. 990, pp. 15-22. [cited by applicant]
Amir et al., “Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2,” Nature Genetics, Oct. 1999, 23:185-188. [cited by applicant]
Baker, M., “Digital PCR hits its stride,” Nature Methods, Jun. 2012, 9(6):541-544. [cited by applicant]
Boutin et al., “Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors,” Human Gene Th… [cited by applicant]
Carter, B.J., “Adeno-associated virus vectors,” Current Opinion in Biotechnology, 1992, 3(5): 533-539. [cited by applicant]
Chu et al., “SV40 DNA transfection of cells in suspension: analysis of efficiency of transcription and translation of T-antigen,” Gene (1981) 13:197-202. [cited by applicant]
Clark et al., “A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors,” Gene Therapy (1996) 3:1124-1132. [cited by applicant]
Crowther et al., “An Adeno-Associated Virus-Based Toolkit for Preferential Targeting and Manipulating Quiescent Neural Stem Cells in the Adult Hippocampus,” Stem Cell Reports, Mar. 13, 2018, vol. 10, pp. 1146-1159. [cited by applicant]
De et al., “High Levels of Persistent Expression of α1-Antitrypsin Mediated by the Nonhuman Primate Serotype rh. 10 Adeno-associated Virus Despite Preexisting Immunity to Common Human Adeno-associated Viruses,” Mol. The… [cited by applicant]
Duque et al., “A Large Animal Model of Spinal Muscular Atrophy and Correction of Phenotype,” Ann Neurol 2015, 77:399-414. [cited by applicant]
Eaves et al., “Isolation and Properties of an Exocellular Nuclease of Serratia Marcescens,” J. Bact. 1963, 85, 273-278. [cited by applicant]
Encinas et al., “Gene regulation in adult neural stem cells. Current challenges and possible applications,” Advanced Drug Delivery Reviews, 2017, 120: 118-132. [cited by applicant]
Ebinger et al., “Headache and Backache After Lumbar Puncture in Children and Adolescents: A Prospective Study,” Pediatrics, Jun. 2004, 113(6):1588-1592. [cited by applicant]
Farkas et al., “Multimode light microscopy and the dynamics of molecules, cells, and tissues,” Ann. Rev. Physiol. (1993) 55:785-817. [cited by applicant]
Farrar et al., “Emerging Therapies and Challenges in Spinal Muscular Atrophy,” Ann Neurol., 2017, 81: 355-368. [cited by applicant]
Foust et al., “Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN,” Nature Biotechnol., Mar. 2010, 28(3): 271-274, 11 pages provided. [cited by applicant]
Foust et al., “Therapeutic AAV9-mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS,” Molecular Therapy, Dec. 2013, vol. 21, No. 12, 2148-2159. [cited by applicant]
Gao et al., “Clades of Adeno-associated viruses are widely disseminated in human tissues,” J. Virol (2004) 78(12): 6381-6388. [cited by applicant]
GenBank NCBI Reference Sequence AF085716.1, Adeno-associated virus 5 DNA binding trs helicase (Rep22) and capsid protein (VP1) genes, complete cds, Feb. 9, 1999, 3 pages. [cited by applicant]
GenBank NCBI Reference Sequence AX753246.1, Sequence 1 from Patent EP1310571, Jun. 23, 2003, 2 pages. [cited by applicant]
GenBank NCBI Reference Sequence AX753249.1, Sequence 4 from Patent EP1310571, Jun. 23, 2003, 2 pages. [cited by applicant]
GenBank NCBI Reference Sequence NC_001401.2, Adeno-associated virus-2, complete genome, Aug. 13, 2018, 6 pages. [cited by applicant]
GenBank NCBI Reference Sequence NC_001829.1, Adeno-associated virus-4, complete genome, Aug. 13, 2018, 3 pages. [cited by applicant]
GenBank NCBI Reference Sequence NC_001862.1, Adeno-associated virus 6, complete genome, Jan. 12, 2004, 3 pages. [cited by applicant]
GenBank NCBI Reference Sequence NC_002077.1, Adeno-associated virus-1, complete genome, Aug. 13, 2018, 3 pages. [cited by applicant]
GenBank NCBI Reference Sequence: NM_000344.2, [cited by applicant]
GenBank NCBI Reference Sequence NM_017411.4, [cited by applicant]
Giuliano and Taylor, “Measurement and manipulation of cytoskeletal dynamics in living cells,” Curr. Op. Cell Biol., 1995, 7:4-12. [cited by applicant]
Giuliano et al., “Fluorescent protein biosensors: measurement of molecular dynamics in living cells,” Annu. Rev. Biophys. Biomol. Struct. (1995) 24:405-434. [cited by applicant]
Glanzman et al., “The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (Chop Intend): test development and reliability.” Neuromuscular Disorders, Mar. 2010, 20(3):155-161, 11 pages provided. [cited by applicant]
Graham et al., “A new technique for the assay of infectivity of human adenovirus 5 DNA, ” Virology, (1973) 52:456-467. [cited by applicant]
Gurney et al., “Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation,” Science, Jun. 1994, vol. 264, pp. 1772-1775. [cited by applicant]
Guy et al., “Reversal of Neurological Defects in a Mouse Model of Rett Syndrome,” Science, Feb. 2007, 315(5815): 1143-1147. [cited by applicant]
Hahn et al., “Patterns of elevated free calcium and calmodulin activation in living cells,” Nature (1992) 359:736-738. [cited by applicant]
Hermens et al., “Purification of Recombinant Adeno-Associated Virus by Iodixanol Gradient Ultracentrifugation Allows Rapid and Reproducible Preparation of Vector Stocks for Gene Transfer in the Nervous System,” Human Ge… [cited by applicant]
Hermonat et al., “Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells,” PNAS USA, Oct. 1984, 81:6466-6470. [cited by applicant]
Hildebrandt et al., “Targeting of neural stem cells in the hippocampus of adult rats by custom-made Ad vectors,” Brain Struct Funct (2010) 215:105-113. [cited by applicant]
Jeune et al., “Pre-existing Anti-Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy,” Human Gene Therapy Methods, Apr. 2013, 24(2):59-67. [cited by applicant]
Kaplitt et al., “Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial” Lancet (2007) 369:2097-2105. [cited by applicant]
Kiechl-Kohlendorfor et al., “Cerebrospinal Fluid Leakage After Lumbar Puncture in Neonates: Incidence and Sonographic Appearance,” American Journal of Roentgenology, 2003, 181: 231-234. [cited by applicant]
Kotterman et al., “Enhanced selective gene delivery to neural stem cells in vivo by an adeno-associated viral variant,” Development (2015) 142: 1885-1892. [cited by applicant]
Laughlin et al., “Cloning of infectious adeno-associated virus genomes in bacterial plasmids,” Gene, 1983, 23:65-73. [cited by applicant]
Lebkowski et al., “Adeno-Associated Virus: a Vector System for Efficient Introduction and Integration of DNA into a Variety of Mammalian Cell Types,” Mol Cell Biol, Oct. 1988, 8(10): 3988-3996. [cited by applicant]
Lefebvre et al., “Correlation between severity and SMN protein level in spinal muscular atrophy,” Nature Genetics, (1997) 16:265-269. [cited by applicant]
Lefebvre et al., “Identification and Characterization of a Spinal Muscular Atrophy-Determining Gene,” Cell, Jan. 1995, 80:155-65. [cited by applicant]
Levitt et al., “Definition of an efficient synthetic poly(A) site,” Genes & Development, 1989, 3:1019-1025. [cited by applicant]
Lock et al., “Absolute Determination of Single-Stranded and Self-Complementary Adeno-Associated Viral Vector Genome Titers by Droplet Digital PCR,” Human Gene Therapy Methods (Apr. 2014) 25(2):115-125. [cited by applicant]
Lorson et al., “A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy,” PNAS, May 1999, 96: 6307-6311. [cited by applicant]
Lowes et al., “Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy,” Pediatric Neurology (2019) 98: 39-45. [cited by applicant]
Marks, Jr., W.J. et al., “Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial,” Lancet Neurol. (2010) 9:1164-1172. [cited by applicant]
Matagne et al., “A codon-optimized Mecp2 transgene corrects breathing deficits and improves survival in a mouse model of Rett syndrome,” Neurobiology of Disease, 2017, vol. 99, pp. 1-11. [cited by applicant]
McCarty et al., “Sequences Required for Coordinate Induction of Adeno-Associated Virus p19 and p40 Promoters by Rep Protein,” J Virol., Jun. 1991, 65(6):2936-2945. [cited by applicant]
McLaughlin et al., “Adeno-Associated Virus General Transduction Vectors: Analysis of Proviral Structures,” J Virol, Jun. 1988, 62(6):1963-1973. [cited by applicant]
Mendell et al., “Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering avxs-101,” Protocol No. AVXS-101-CL-101 (formerly AVXS-101), IND No. 15699, Version 14.0, Apr. 21, 2016, 63 pages. [cited by applicant]
Mendell et al., “Phase I Gene Transfer clinical trial for spinal muscular atrophy type 1 delivering the survival motor neuron gene by self-complementary AAV9,” The Research Institute at Nationwide Children's Hospital Ce… [cited by applicant]
Mendell, J.R., “Phase I Gene Transfer clinical trial for spinal muscular atrophy type 1 delivering the survival motor neuron gene by self-complementary AAV9,” The Research Institute at Nationwide Children's Hospital Cen… [cited by applicant]
Mendell et al., “Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy,” N Engl J Med 2017, 337(18): 1713-1722. [cited by applicant]
Mendell et al., Supplementary Appendix to Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy, N Engl J Med 2017, 337(18): 1713-1722, 4 pages. [cited by applicant]
Mingozzi et al., “Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B,” Mol Ther, Jul. 2012, 20(7):1410-1416. [cited by applicant]
Monani et al., “A Single Nucleotide Difference That Alters Splicing Patterns Distinguishes the SMA Gene SMN1 From the Copy Gene SMN2,” Human Molecular Genetics, 1999, vol. 8, No. 7, 1177-1183. [cited by applicant]
Monani, U.R., “Spinal Muscular Atrophy: A Deficiency in a Ubiquitous Protein; a Motor Neuron-Specific Disease,” Neuron, Dec. 2005, 48: 885-896. [cited by applicant]
Monteilhet et al., “A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8,” Mol. Therapy, Nov. 2011, 19(11): 2084-2091. [cited by applicant]
Mori et al., “Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein,” Virology, (2004) 330: 375-383. [cited by applicant]
Muzyczka, N., “Use of adeno-associated virus as a general transduction vector for mammalian cells,” Curr. Top. Microbiol. Immunol (1992) 158:97-129. [cited by applicant]
Myslinski et al., “An unusually compact external promoter for RNA polymerase III transcription of the human H1RNA gene,” Nucleic Acids Research, 2001, 29(12): 2502-2509. [cited by applicant]
Nestle et al., “An extracellular nuclease from Serratia marcescens. II. Specificity of the enzyme,” J. Biol. Chem., Oct. 1969, 244(19), 5219-5225. [cited by applicant]
Oertle et al., “Nogo-A Inhibits Neurite Outgrowth and Cell Spreading with Three Discrete Regions,” The Journal of Neuroscience, Jul. 2003, 23(13): 5393-5406. [cited by applicant]
Oprea et al., “Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy,” Science, Apr. 2008, 320(5875): 524-527, 11 pages provided. [cited by applicant]
Pacak et al., “Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo,” Circ. Res, (2006) 99(4): e3-e9. [cited by applicant]
Park et al., “Spinal Muscular Atrophy: New and Emerging Insights from Model Mice,” Curr Neurol Neurosci Rep., Mar. 2010, 10(2): 108-117, 14 pages provided. [cited by applicant]
Paul et al., “Increased Viral Titer Through Concentration of Viral Harvests from Retroviral Packaging Lines,” Human Gene Therapy, 1993, vol. 4, No. 5, pp. 609-615. [cited by applicant]
Perrin et al., “An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system,” Vaccine (1995) 13:1244-1250. [cited by applicant]
Potter et al., “A simplified purification protocol for recombinant adeno-associated virus vectors,” Molecular Therapy—Methods & Clinical Development, vol. 1, Jan. 2014, pp. 14034, 8 pages. [cited by applicant]
Prior et al., “A Positive Modifier of Spinal Muscular Atrophy in the SMN2 Gene,” The American Journal of Human Genetics, Sep. 2009, 85, 408-413. [cited by applicant]
Proll et al., “Potential of label-free detection in high-content-screening applications,” Journal of Chromatography, Aug. 2007, 1161(1-2): 2-8. [cited by applicant]
Qu et al., “Scalable Downstream Strategies for Purification of Recombinant Adeno-Associated Virus Vectors in Light of the Properties,” Current Pharmaceutical Biotechnology, 2015, 16(8), 684-695. [cited by applicant]
Rao et al., “Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease”, J Manag Care Spec Pharm, Dec. 2018, 24(12-a Suppl): S3-S16. [cited by applicant]
Rashnonejad et al., “Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene,” Mol Biotechnol (2016) 58: 30-36. [cited by applicant]
Ruffing et al., “Mutations in the carboxy terminus of adeno-associated virus 2 capsid proteins affect viral infectivity: lack of an RGD integrin-binding motif,” Journal of General Virology (1994), 75, 3385-3392. [cited by applicant]
Samulski et al., “Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression,” J. Virol, Sep. 1989, 63(9): 3822-3828. [cited by applicant]
Samulski et al., “Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells,” Proc. Natl. Acad. Sci. USA (1982), 79(6): 2077-281. [cited by applicant]
Schmidt et al., “Selective Targeting of Adenoviral Vectors to Neural Precursor Cells in the Hippocampus of Adult Mice: New Prospects for In Situ Gene Therapy,” Stem Cells, 2007, 25: 2910-2918. [cited by applicant]
Senapathy and Carter, “Molecular Cloning of Adeno-associated Virus Variant Genomes and Generation of Infectious Virus by Recombination in Mammalian Cells,” J. Biol. Chem., Apr. 1984, 259(7):4661-4666. [cited by applicant]
Singh et al., “A Multi-Exon-Skipping Detection Assay Reveals Surprising Diversity of Splice Isoforms of Spinal Muscular Atrophy Genes,” PLoS One, 7(11):e49595, 17 pages, 2012. [cited by applicant]
Srivastava et al., “Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome,” J Virol., Feb. 1983, 45(2): 555-564. [cited by applicant]
Strobel et al., “Comparative Analysis of Cesium Chloride- and Iodixanol-Based Purification of Recombinant Adeno-Associated Viral Vectors for Preclinical Applications,” Human Gene Therapy Methods, 26(4): 147-157, 2015. [cited by applicant]
Sun et al., “Engineered viral vectors for functional interrogation, deconvolution, and manipulation of neural circuits,” Curr. Opin. Neurobiol. 2018, 50: 163-170. [cited by applicant]
Sykes et al., “Quantitation of targets for PCR by use of limiting dilution,” Biotechniques, 1992, 13(3): 444-449. [cited by applicant]
Tomono et al., “Ultracentrifugation-free chromatography-mediated large-scale purification of recombinant adeno-associated virus serotype 1 (rAAV1),” Molecular Therapy—Methods & Clinical Development, (2016) 3:15058, 8 pa… [cited by applicant]
Tratschin et al., “A Human Parvovirus, Adeno-Associated Virus, as a Eucaryotic Vector: Transient Expression and Encapsidation of the Procaryotic Gene for Chloramphenicol Acetyltransferase,” Mol Cell Biol., 1984, 4(10): … [cited by applicant]
Tratschin et al., “Adeno-Associated Virus Vector for High-Frequency Integration, Expression, and Rescue of Genes in Mammalian Cells,” Mol Cell Biol., Nov. 1985, 5(11): 3251-3260. [cited by applicant]
UniProt Accession No. Q16637 (SMN_Human), Nov. 1, 1996, 23 pages. [cited by applicant]
United States Pharmacopeia <787>, Subvisible Particulate Matter In Therapeutic Protein Injections, May 2021, 3 pages. [cited by applicant]
United States Pharmacopeia <785>, Osmolality and Osmolarity, USP32-NF27 p. 305, Pharmacopeial Forum: vol. No. 34(5) p. 1251, http://www.uspbpep.com/usp32/pub/data/v32270/usp32nf27s0_c785.html, 4 pages, May 11, 2021. [cited by applicant]
United States Pharmacopeia <791>, pH, USP29-NF24 p. 2730, Pharmacopeial Forum: vol. No. 29(6) p. 2037, http://www.uspbpep.com/usp29/v29240/usp29nf24s0_c791.html, May 11, 2021. [cited by applicant]
Waggoner et al., “Multiparameter fluorescence imaging microscopy: reagents and instruments,” Hum. Pathol. (1996) 27:494-502. [cited by applicant]
Wang et al., “Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart,” Nature Biotech (2005) 23(3): 321-328. [cited by applicant]
Worgall et al., “Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis by CNS Administration of a Serotype 2 Adeno-Associated Virus Expressing CLN2 cDNA, ” Human Gene Therapy, May 2008, 19(5):463-474. [cited by applicant]
Wright et al., “Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65,” Current Gene Therapy, 2010, 10: 341-349. [cited by applicant]
Wright et al., “Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment,” Biomedicines 2014, 2, 80-97. [cited by applicant]
Miyake and Shimada, “3.Gene Delivery and Expression Series Viral Vector Mediated Gene Delivery and Expression(4)”, Nihon Ika Daigaku Igakkai Zasshi, 2012, vol. 8, pp. 150-156 (with English abstract). [cited by applicant]
Mizutani, Ken'ichi, “Neural Progenitor Cells”, Brain Science Dictionary, [Online] Apr. 17, 2017, Internet, retrieved from: https://bsd.neuroinf.jp/w/index.php?title=%E7%A5%9E%E7%B5%8C%E5%89%8D%E9%A7%86%E7%B4%B0%E8%83%9E… [cited by applicant]
Novartis, “Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow, and maintain airway protection,” Mar. … [cited by applicant]
U.S. Department of Health and Human Services et al., “Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions. Annex 3(R1) Test for Particulate Contamination: Subvisible Particles General Ch… [cited by applicant]
Clark, K.R., et al., “Highly Purified Recombinant Adeno-Associated Virus Vectors Are Biologically Active and Free of Detectable Helper and Wild-Type Viruses,” Hum Gene Ther., Apr. 1999, 10(6): 1031-1039. [cited by applicant]
Embury, C.M., et al., “Cathepsin B Improves β-Amyloidosis and Learning and Memory in Models of Alzheimer's Disease” Journal of Neuroimmune Pharmacology, 2017, vol. 12, pp. 340-352. [cited by applicant]
Kiyota, T., et al., “AAV2/1 CD74 Gene Transfer Reduces β-amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease,” Molecular Therapy, 2015, vol. 23(11), pp. 1712-1721 (10 pages provided). [cited by applicant]
Robert, M-A. et al., “Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms,” Biotechnology Journal, 2017, vol. 12, 1600193, 16 pages. [cited by applicant]
Schnepp, B. and Clark, K.R., “Highly Purified Recombinant Adeno-Associated Virus Vectors. Preparation and Quantitation,” Methods Mol Med., 2002, 69: 427-443. [cited by applicant]
AveXis, Inc., AveXis, Inc.'s Initial Response to the Form FDA 483 Issued on Aug. 2, 2019 to the San Diego, CA Quality Control Laboratory, FEI: 3014617030, Investigators: Scott T. Ballard and Mibaly S. Ligmond, dated Aug… [cited by applicant]
Department of Health and Human Services, Food and Drug Administration, Form FDA 483, dated Aug. 2, 2019, to the San Diego, CA Quality Control Laboratory, FEI No. 3014617030, 5 pages. [cited by applicant]
Keown, A., “Kaspar Brothers Impeded Internal Investigation into Data Manipulation, Novartis Claims,” BioSpace, Sep. 25, 2019, 6 pages, retrieved from https://www.biospace.com/article/novartis-continues-to-point-its-fing… [cited by applicant]